CAMBRIDGE, Mass. (September 28, 2012) – InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and neurotrauma, today announced the appointment of Bill D’Agostino as Senior Director of Manufacturing & Engineering.
An executive leader focused on rapid market growth, Mr. D’Agostino joins InVivo following fifteen years at Covidien and, most recently, seven years at Angiotech Pharmaceuticals as Vice President, Engineering. In his career to date, Mr. D’Agostino has launched more than 100 new polymer products including families of biodegradable sutures.
Mr. D’Agostino is a seasoned professional in medical devices and pharmaceutical excelling in all aspects of Research & Development, Engineering, GMP Operations and Quality Assurance, and has a wealth of expertise on technologies such as hydrogels and biodegradable sutures. He has worked on every stage of the product life cycle including end-user requirements, risk management, feasibility, development, quality systems, design verification, pilot manufacturing, validations, regulatory approvals, clinical field testing, full manufacturing, product launch, marketing and post-market surveillance.
Said InVivo CEO Frank Reynolds, “Bill has a unique history and expertise in getting products to market. I am confident that his wide-ranging experience with all aspects of commercializing medical devices and with FDA submissions will play a pivotal role as we plan to begin a clinical trial for “First in Man” use of biopolymer scaffolding to treat acute SCI.”
“There is no time like the present for driving innovation to a higher level, and InVivo Therapeutics is just the company to do it considering the multiple products in our pipeline and the significant unmet medical needs in neurotrauma,” said Mr. D’Agostino.
Mr. D’Agostino is a licensed Professional Engineer (PE), with a Bachelor of Science degree in Chemical Engineering & Materials Engineering from the University of Connecticut. He received his MBA with the highest honors from the University of Dallas.
About the Neuro-Spinal Scaffold
Following an acute spinal cord injury, the biodegradable Neuro-Spinal Scaffold is surgically implanted at the epicenter of the wound and acts as a physical substrate for nerve sprouting. Appositional healing to spare spinal cord tissue, decreased post-traumatic cyst formation, and decreased spinal cord tissue pressure have been demonstrated in preclinical models of spinal cord contusion injury. The Neuro-Spinal Scaffold, an investigational device, has received a Humanitarian Use Device designation and is currently being studied in a pilot study for the treatment of complete (AIS A) traumatic acute spinal cord injury.
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a pioneering biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, ScD, Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, MD, who then was at Boston Children’s Hospital and who now is affiliated with Massachusetts General Hospital. In 2011 the company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. The publicly-traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.
Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as “believe,” “anticipate,” “intend,” “estimate,” “will,” “may,” “should,” “expect” and similar expressions, and include statements regarding the enrollment of additional patients in the scaffold pilot study following the reopening of enrollment and its ability to conduct a second pivotal study. Any forward-looking statements contained herein are based on current expectations, and are subject to a number of risks and uncertainties. Factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to successfully open additional clinical sites for enrollment and to enroll additional patients; the timing of the Institutional Review Board process; the Company’s ability to obtain FDA approval to commercialize its products; the Company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company’s products and technology in connection with spinal cord injuries; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and other risks associated with the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies identified and described in more detail in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013, as amended, and its other filings with the SEC, including the Company’s Form 10-Qs and current reports on Form 8-K. The Company does not undertake to update these forward-looking statements.